29.07.2021 SYNLAB AG  DE000A2TSL71

DGAP-News: SYNLAB: SYNLAB and AXA Partners enter a partnership to enhance safe travel this summer


 

DGAP-News: SYNLAB AG / Key word(s): Alliance
SYNLAB: SYNLAB and AXA Partners enter a partnership to enhance safe travel this summer

29.07.2021 / 10:01
The issuer is solely responsible for the content of this announcement.


  • SYNLAB supports AXA Partners in enabling customers and employees to resume travel safely
  • SYNLAB and AXA Partners leverage SYNLAB's broad international laboratory network and medical expertise to provide safe and easy COVID-19 testing, ensuring delivery of PCR test results within 24 to 48 hours

SYNLAB, Europe's leading medical diagnostic services provider, and AXA Partners enter a partnership to facilitate safe and easy travelling for customers and employees. AXA Partners is part of the AXA Group, a global leader in insurance and asset management, with more than 9,000 employees serving customers worldwide.

Leveraging SYNLAB's broad laboratory network, AXA Partners' customers and employees are being offered comprehensive COVID-19 testing services in more than 10 European countries, including Spain, Portugal and France and covering around 900 testing centres. The partnership may be extended to include further countries.

PCR tests are considered gold standard for COVID-19 testing, providing the highest possible sensitivity and specificity. A negative PCR test result ensures that customers and employees are not infected with SARS-CoV-2, which helps to protect their environment. In addition, it can also facilitate their on-/homeward journey and border crossing. Besides PCR testing, the partnership also includes antigen tests and self-administrated test kits, if country regulation permits.

AXA Partners' customers and employees can find SYNLAB laboratories and sample collection points through AXA Partners' vetted medical network, whereby SYNLAB - as the preferred partner in testing for COVID-19 - is ranked first on search results.

Mathieu Floreani, CEO of SYNLAB, says: "At a time when people around the world want to resume travel and different variants of the SARS-CoV-2 virus are spreading, testing remains crucial. We are pleased that AXA Partners has chosen SYNLAB as the preferred provider for testing. Together, we will make travel as safe as possible for their customers and employees."

Julia d'Astorg, Chief International Medical Services Officer, AXA Partners: "We at AXA Partners continually strive to provide a best-in-class health services to our customers. This means that when looking for a Partner, we always ensure that their standard of service, ethos and ability to promptly innovate are aligned with ours. We are very happy to have found that in SYNLAB."

For more information:

Media contact:
Diana Tabor, FTI Consulting          
+49 (0) 151 46693856
[email protected]
Investor contact:
Mark Reinhard, SYNLAB
+49 (0) 170 118 3753
[email protected]
 


About SYNLAB

  • SYNLAB, (ISIN: DE000A2TSL71, SYMBOL: SYAB) is the largest European clinical laboratory and medical diagnostic services company and offers a full range of innovative and reliable medical diagnostics for patients, practising doctors, clinics and the pharmaceutical industry.
  • Providing the leading level of service within the industry, SYNLAB is the partner of choice for diagnostics in human and veterinary medicine. The Group continuously innovates medical diagnostic services for the benefit of patients and customers.
  • SYNLAB operates in 36 countries across four continents and holds leading positions in most markets. More than 20,000 employees, including over 1,200 medical experts, as well as a large number of other specialists such as biologists, chemists and laboratory technicians, contribute every day to the Group's worldwide success. SYNLAB carries out ~500 million laboratory tests per year and achieved revenues of EUR 2.6 billion in 2020.
  • More information can be found on www.synlab.com


29.07.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: SYNLAB AG
Moosacher Straße 88
80809 Munich
Germany
Phone: +49 1701183753
E-mail: [email protected]
Internet: www.synlab.com/
ISIN: DE000A2TSL71
WKN: A2TSL7
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1222522

 
End of News DGAP News Service

1222522  29.07.2021 

fncls.ssp?fn=show_t_gif&application_id=1222522&application_name=news&site_id=boersengefluester_html


Die wichtigsten Finanzdaten auf einen Blick
  2016 2017 2018 2019 2020 2021 2022e
Umsatzerlöse1 0,00 0,00 1.807,90 1.906,10 2.621,20 3.764,92 3.000,00
EBITDA1,2 0,00 0,00 382,90 397,40 679,20 1.179,89 722,00
EBITDA-Marge3 0,00 0,00 21,18 20,85 25,91 31,34 24,07
EBIT1,4 0,00 0,00 138,80 71,90 315,50 914,53 505,00
EBIT-Marge5 0,00 0,00 7,68 3,77 12,04 24,29 16,83
Jahresüberschuss1 0,00 0,00 -42,10 -108,00 259,10 627,54 278,00
Netto-Marge6 0,00 0,00 -2,33 -5,67 9,88 16,67 9,27
Cashflow1,7 0,00 0,00 120,30 238,60 904,70 1.011,70 0,00
Ergebnis je Aktie8 0,00 0,00 -0,19 -0,49 1,16 2,82 1,20
Dividende8 0,00 0,00 0,00 0,00 0,00 0,33 0,35
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2021 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Deloitte

INVESTOR-INFORMATIONEN
©boersengefluester.de
Synlab
WKN Kurs in € Einschätzung Börsenwert in Mio. €
A2TSL7 14,120 3.137,78
KGV 2023e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
13,45 10,07 1,34 14,19
KBV KCV KUV EV/EBITDA
1,39 3,10 0,83 3,53
Dividende '22 in € Dividende '23e in € Div.-Rendite '23e
in %
Hauptversammlung
0,35 0,35 2,48 16.05.2022
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
12.05.2022 11.08.2022 10.11.2022 16.03.2022
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
8,00% -9,43% -40,17% -34,63%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu SYNLAB AG  ISIN: DE000A2TSL71 können Sie bei EQS abrufen


Medtech , A2TSL7 , SYAB , XETR:SYAB